CCT301-59

N/A

Report date: 2024/10/30 20:00:43

Base Information

Drug NameCCT301-59
Drug Alias NameCCT301-59 ROR2CCT301-59
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTyrosine-protein kinase transmembrane receptor ROR2 inhibitorsWnt signalling pathway modulators
TargetsTyrosine-protein kinase transmembrane receptor ROR2
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesF1 OncologyBioAtla Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Sinobioway Sunterra BiotechExuma Biotech Corp
Active IndicationsN/A
Inactive IndicationsSolid tumoursUrinary Bladder NeoplasmsPancreatic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A